PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presen... (nebulizer such as the customized small d...)

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS

Date:5/20/2009

nebulizer, such as the customized small droplet generating eFlow electronic nebulizer," stated Dr. Alexander Moeller, head of the Research Division, Respiratory Medicine at the University Children's Hospital Zurich, Switzerland.

Previous DSCG therapies were only moderately effective, since the interaction of the very hygroscopic properties of DSCG with the drug delivery system were not understood.

"We believe our novel, higher concentrated, low volume DSCG formulation delivered via an optimized Investigational eFlow Nebulizer System opens new treatment avenues and perspectives for patients and physicians. This expectation is further supported by newly published data on a potential antiviral efficacy of DSCG that may be particularly important in the treatment of pediatric asthma," added Dr. Manfred Keller, chief scientific officer and executive vice president of PARI Pharma.

At ATS, PARI Pharma also presented in-vitro data comparing IsoCrom (1%) with a novel, higher concentrated (6%), low volume DSCG formulation that requires significantly less nebulization time than IsoCrom. The results of this in-vitro study using 45mg/0.75ml may allow the option for twice-daily administration in less than 2.5 minutes.

IsoCrom & ICS Comparative Study Results

Data from a randomized, open-label, Phase II, six-month study comparing efficacy and safety of an IsoCrom solution versus inhaled steroids was presented by researchers from the pediatric department of the University Hospital Zurich, Switzerland. Twenty eight children (11.9 +/- 2.8 years) with stable atopic asthma were randomized to inhale either IsoCrom, delivered at a dose of 60 mg per day administered in three inhalations of 2ml using a customized small droplet Investigational eFlow Nebulizer System, or inhaled corticosteroids (ICS) without dose adjustments administered in two inhalations using a metered dose Inhaler (MDI) via a holding
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. ePharmaSolutions Clinical Trial Investigator Portal Wins Bio-IT World 2009 Best Practice Award
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
4. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
5. Pharmasset Reports Fiscal Year End 2008 Financial Results
6. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
7. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
8. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
9. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
10. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
11. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)

Post Your Comments:

PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presen...(nebulizer such as the customized small d...),Health